To explore the potential of combined ATR and WEE1 inhibition for lung cancer treatment, we used a panel of four lung cancer cell lines with previously identified large differences in sensitivity to the WEE1 inhibitor MK1775 (sensitive SW900 > H1975 > A549 > H460 resistant) [26]. This evidence concerns the gene ATR and lung carcinoma.